Curevac (CVAC) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Curevac in November 2026.
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Curevac (CVAC) Stock Forecast
Analyst price target, next 12 months
$4.68
+0.5% vs today's $4.66
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Curevac have a consensus 12-month target of $4.68, above the current price of $4.66.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 6 Jan 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding CureVac's stock, anticipating a slight increase in value.
Financial Health
CureVac is showing strong revenue, cash flow, and profit margins, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
